MedCity News March 24, 2024
Frank Vinluan

Lack of automation is the top challenge facing commercialization teams, according to a survey of executives at U.S.-based pharma companies. The survey was conducted in late 2023 and results were reported this month.

The commercial teams of pharmaceutical companies are looking for more data analytics and business insights and they’re willing to spend more money to do it. Those are some of the findings of a recent survey of pharma industry executives at U.S.-based companies.

The survey was conducted by independent survey company Global Surveyez, but it was commissioned by Verix, a Santa Clara, California-based company that provides an AI-based technology platform that supports life sciences commercial operations. In other words, it has a financial interest in the topics covered...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Analytics, Pharma, Pharma / Biotech, Survey / Study, Technology, Trends
Navigating the Shift: 2026 Medicare Drug Pricing and the Future of Pharmacy
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety

Share Article